Drug Trial Radar · NCT01896479
A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer
Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
247
Actual
Start
Feb 25, 2015
Primary completion
Jul 15, 2020
Study completion Jan 31, 2035
Sponsor
- Lead sponsor
- ExelixisIndustry
- Sponsor type
- Industry
- First posted
- Jul 11, 2013
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to evaluate the efficacy and safety of oral cabozantinib at a 60 mg dose compared with a 140 mg dose in subjects with progressive, metastatic MTC. It will test if the lower dose results in similar progression free survival (PFS) and overall response rate (ORR) with fewer adverse events compared to the PFS, ORR and adverse events found in previous clinical trials of 140 mg.
Conditions
- Medullary Thyroid Cancer
Interventions
Cabozantinib (XL184) 140 mgDrug
Cabozantinib (XL184) 60 mgDrug
Placebo tabletDrug
Placebo capsuleDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS) Per Blinded Independent Radiology Committee (BIRC) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)Time frame: Median time of follow-up (from the date of randomization of the first participant through primary data cut off [15 July 2020]) was 30.2 months
Locations
49 sites in 14 countries. Site status is shown where the registry gives one.
Site not named
St Leonards, New South Wales, Australia
Site not named
Herston, Queensland, Australia
Site not named
Kurralta Park, South Australia, Australia
Site not named
Parkville, Victoria, Australia
Site not named
Toronto, Canada
Site not named
Québec, Quebec, Canada
Site not named
Osijek, Croatia
Site not named
Zagreb, Croatia
Site not named
Zagreb, Croatia
Site not named
Dijon, France
Site not named
Paris, France
Site not named
Strasbourg, France
Site not named
Bordeaux, Gironde, France
Site not named
Angers, Maine-et-Loire, France
Site not named
Lyon, Rhône, France
Site not named
Villejuif, Val-de-Marne, France
Site not named
Budapest, Hungary
Site not named
Debrecen, Hungary
Site not named
Jerusalem, Israel
Site not named
Petah Tikva, Israel
Site not named
Safed, Israel
Site not named
Milan, Italy
Site not named
Padua, Italy
Site not named
Torino, Italy
Site not named
Catania, CT, Italy
Site not named
Roma, RM, Italy
Site not named
Siena, SI, Italy
Site not named
Pisa, Tuscany, Italy
Site not named
Groningen, Netherlands
Site not named
Amsterdam, North Holland, Netherlands
Site not named
Leiden, South Holland, Netherlands
Site not named
Poznan, Greater Poland Voivodeship, Poland
Site not named
Gliwice, Silesian Voivodeship, Poland
Site not named
Bucharest, Romania
Site not named
Bucharest, Romania
Site not named
Cluj-Napoca, Romania
Site not named
Timișoara, Romania
Site not named
Novosibirsk, Russia
Site not named
Obninsk, Russia
Site not named
Saint Petersburg, Russia
Showing 40 of 49 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.